DaunoXome (liposomal daunorubicin) plus Ara-C [cytarabine] versus daunorubicin plus Ara-C in elderly AML [acute myeloid leukaemia] patients. a randomized phase III study

Trial Profile

DaunoXome (liposomal daunorubicin) plus Ara-C [cytarabine] versus daunorubicin plus Ara-C in elderly AML [acute myeloid leukaemia] patients. a randomized phase III study

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2008

At a glance

  • Drugs Daunorubicin liposomal (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top